Advanced Biomed Inc. (ADVB) intrinsic value & 10-year financials
Advanced Biomed Inc. (ADVB) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.98
- Market cap
- $81.7M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 1242.0%
- Free cash flow (FY2025)
- -$5.9M
ADVB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$3.3M | -$0.16 | -$5.9M | — | 2167.9% |
| FY2024 | — | -$2.8M | -$0.14 | -$2.2M | — | 316.1% |
| FY2023 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Advanced Biomed Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Advanced Biomed Inc. returns on capital have been average, hovering around 12.4% ROIC over the decade.
Advanced Biomed Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Advanced Biomed Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.